We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

LumiraDx

LumiraDx develops, manufactures and commercializes industry-leading point of care (POC) diagnostic platforms that use... read more Featured Products: More products

Download Mobile App





LumiraDx Launches Rapid Onsite COVID-19 Surveillance Test for Simultaneous Testing of Five Samples on Portable Instrument

By LabMedica International staff writers
Posted on 03 Sep 2021
LumiraDx (London, UK) has announced the US launch of its COVID-19 Surveillance Test, for environments such as schools and workplaces. More...


The LumiraDx SARS-CoV-2 Ag Surveillance Test allows simultaneous testing of up to five samples on a small, portable instrument with cost per sample as low as USD 4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using an affordable, easy-to-use, onsite testing platform. LumiraDx's announcement comes at a time when schools across the US are assessing how to both bring students back to in-person learning while also monitoring for outbreaks to ensure they can stay safe and open.

The LumiraDx SARS-CoV-2 Ag Surveillance Test, used on the LumiraDx Platform, has demonstrated 100.0% positive agreement and 96.6% negative agreement with its comparator, the LumiraDx SARS-CoV-2 Ag Test. It allows rapid, high-sensitivity surveillance testing in both CLIA and non-CLIA certified settings. The company also offers the LumiraDx SARS-CoV-2 Ag Test and SARS-CoV-2 Ab Test for clinical use in CLIA waived settings on the LumiraDx Platform, both of which were granted Emergency Use Authorization by the FDA.

“Our rapid onsite COVID-19 Surveillance Test offers options that can fit into a variety of different use-cases to support a safe return to school or the workplace and instill confidence in groups about their environment,” said Pooja Pathak, LumiraDx Chief Product Officer. “By pooling up to five samples at one time, the LumiraDx SARS-CoV-2 Ag Surveillance test provides an efficient, accurate and cost-effective way to implement a surveillance testing program.”

Related Links:
LumiraDx


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.